Trial Profile
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of : Galcanezumab (LY2951742) With a Long-Term Open-Label Extension in Patients With Chronic Cluster Headache
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Nov 2021
Price :
$35
*
At a glance
- Drugs Galcanezumab (Primary)
- Indications Cluster headache
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 22 Nov 2021 Results assessing tolerability and safety findings of subcutaneous galcanezumab in patients with chronic CH who received up to 15 months of treatment, published in the Headache
- 20 Jun 2020 Results presented at the 62nd Annual Scientific Meeting of the American Headache Society
- 20 Jun 2020 Results of post-hoc analysis of efficacy of galcanezumab in patients with chronic cluster headache, presented at the 62nd Annual Scientific Meeting of the American Headache Society.